Compare Moderna, Inc. (MRNA) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Palo Alto Networks Inc — how do they compare? Moderna, Inc. trades at $63.68 (market cap $24.18B), while Palo Alto Networks Inc trades at $383.35 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 12.9× Moderna, Inc.'s market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | PANW | |
|---|---|---|
Market Cap | $24.18B | $312.80B |
Sector | Health | Technology |
52-Week High | $81.80 | $385.04 |
52-Week Low | $22.36 | $141.67 |
Enterprise Value | $20.33B | $311.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Palo Alto Networks (PANW) trades at $385.04, up 5.82% over the past day, reflecting strong momentum amid positive sentiment around AI-driven cybersecurity demand. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, while RSI levels suggest potential overbought conditions. Fundamentally, the company reported revenue of $9.22B in 2025 with a net income margin of 7.95%, though valuation ratios like P/E of 333.74 indicate a premium. Recent news highlights record highs following the Black Hat conference and AI platform launches, though a Chinese regulatory review introduces near-term uncertainty.
The outlook for PANW remains positive given robust revenue growth, AI integration, and Wall Street's bullish consensus, but risks include elevated valuation, integration costs from acquisitions, and geopolitical scrutiny. Investors should weigh the company's leadership in cybersecurity against potential volatility from regulatory developments and high expectations priced into the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
